Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

Cancer Science

Volumn 105, Issue 10, 2014, Pages 1334-1342

  Funahashi, Yasuhiro ^a   Okamoto, Kiyoshi ^b   Adachi, Yusuke ^b   Semba, Taro ^b   Uesugi, Mai ^b   Ozawa, Yoichi ^b   Tohyama, Osamu ^b   Uehara, Taisuke ^b   Kimura, Takayuki ^b   Watanabe, Hideki ^b   Asano, Makoto ^b   Kawano, Satoshi ^b   Tizon, Xavier ^c   Mccracken, Paul J ^a   Matsui, Junji ^b   Aoshima, Ken ^b   Nomoto, Kenichi ^a   Oda, Yoshiya ^a  

^a EISAI INC   (United States)

^b EISAI CO LTD   (Japan)

^c Oncodesign SA   (France)

Author keywords

Breast cancer; Eribulin mesylate; Tumor microenvironment; Tumor vasculature; Vascular remodeling

Indexed keywords

CAPECITABINE; DEOXYCYTIDINE; ERIBULIN; FLUOROURACIL; FURAN DERIVATIVE; KETONE; TUBULIN MODULATOR;

ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; FEMALE; HUMAN; PATHOLOGY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; VASCULAR REMODELING;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FURANS; HUMANS; KETONES; MICE, INBRED BALB C; TUBULIN MODULATORS; TUMOR MICROENVIRONMENT; VASCULAR REMODELING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84911164671     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12488     Document Type: Article

References (39)

1. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-65.
2. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9: 790-803.
3. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-39.
4. Belotti D, Vergani V, Drudis T et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2: 1843-9.
5. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003; 104: 121-9.
6. Pasquier E, Honore S, Pourroy B et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005; 65: 2433-40.
7. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5: 423-35.
8. Hinnen P, Eskens FA. Vascular disrupting agents in clinical development. Br J Cancer 2007; 96: 159-65.
9. Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res 2009; 15: 2594-601.
10. Tozer GM, Prise VE, Wilson J et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61: 6413-22.
11. Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res 2006; 12: 4090-4.
12. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
13. Zakhireh B, Malech HL. The effect of colchicine and vinblastine on the chemotactic response of human monocytes. J Immunol 1980; 125: 2143-53.
14. Liao G, Nagasaki T, Gundersen GG. Low concentrations of nocodazole interfere with fibroblast locomotion without significantly affecting microtubule level: implications for the role of dynamic microtubules in cell locomotion. J Cell Sci 1995; 108: 3473-83.
15. Cortes J, O'Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study. Lancet 2011; 377: 914-23.
16. Donoghue M, Lemery SJ, Yuan W et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial. Clin Cancer Res 2012; 18: 1496-505.
17. Pean E, Klaar S, Berglund EG et al. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Clin Cancer Res 2012; 18: 4491-7.
18. Jordan MA, Kamath K, Manna T et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005; 4: 1086-95.
19. Kuznetsov G, Towle MJ, Cheng H et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004; 64: 5760-6.
20. Towle MJ, Salvato KA, Wels BF et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 2011; 71: 496-505.
21. Towle MJ, Salvato KA, Budrow J et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001; 61: 1013-21.
22. Towle MJ, Nomoto K, Asano M, Kishi Y, Yu MJ, Littlefield BA. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions. Anticancer Res 2012; 32: 1611-9.
23. Nielsen T, Bentzen L, Pedersen M et al. Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging. Clin Cancer Res 2012; 18: 6469-77.
24. Galbraith SM, Maxwell RJ, Lodge MA et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003; 21: 2831-42.
25. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96: 189-95.
26. O'Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 2012; 9: 167-77.
27. Patterson DM, Zweifel M, Middleton MR et al. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res 2012; 18: 1415-25.
28. Fram EK, Herfkens RJ, Johnson GA et al. Rapid calculation of T1 using variable flip angle gradient refocused imaging. Magn Reson Imaging 1987; 5: 201-8.
29. Tofts PS, Brix G, Buckley DL et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-32.
30. Fornier MN. Approved agents for metastatic breast cancer. Semin Oncol 2011; 38(Suppl 2): S3-10.
31. Casazza A, Di Conza G, Wenes M, Finisguerra V, Deschoemaeker S, Mazzone M. Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. Oncogene 2013; 33: 1743-54.
32. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013; 31: 2205-18.
33. Cooke VG, LeBleu VS, Keskin D et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012; 21: 66-81.
34. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.
35. Wykoff CC, Beasley NJ, Watson PH et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 7075-83.
36. Konerding MA, Malkusch W, Klapthor B et al. Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Br J Cancer 1999; 80: 724-32.
37. Sevick EM, Jain RK. Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res 1989; 49: 3506-12.
38. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417-27.
39. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307.